Rifalazil of no benefit in PAD

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1614, 2007-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development potential of rifalazil

By Rothstein David M   Hartman Arthur D   Cynamon Michael H   Eisenstein Barry I  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 2, 2003-02 ,pp. : 255-271

Informa Healthcare

Access to resources Recommend Favorite

Notes From the Launch Pad

By McGivney William T.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 1, Iss. 1, 2003-03 ,pp. : 2-2

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Parogrelil provides promise for patients with PAD

By  

Inpharma, Vol. 1, Iss. 1569, 2007-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Statins improve survival of patients with PAD

By  

Inpharma, Vol. 1, Iss. 1450, 2004-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Inflammation in Peripheral Arterial Disease (PAD)

By  

Current Pharmaceutical Design, Vol. 18, Iss. 28, 2012-09 ,pp. : 4350-4357

Bentham Science Publishers

Access to resources Recommend Favorite